Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1707707 | 0.89 | SMN1; SMN2 (0.75) | KDM4ESMN1; SMN2ALDH1A1HSD17B10TSHR | |
| SCHEMBL1708514 | 0.89 | SMN1; SMN2 (0.62) | KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD | |
| SCHEMBL1707835 | 0.86 | SMN1; SMN2 (0.59) | KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD | |
| SCHEMBL1708521 | 0.85 | SMN1; SMN2 (0.58) | KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD | |
| SCHEMBL15120766 | 0.74 | HSD17B10 (0.68) | KDM4ESMN1; SMN2ALDH1A1HSD17B10TSHR | |
| SCHEMBL1307213 | 0.73 | HSD17B10 (1.00) | KDM4ESMN1; SMN2ALDH1A1HSD17B10TSHR | |
| SCHEMBL14963919 | 0.72 | HSD17B10 (0.73) | KDM4ESMN1; SMN2ALDH1A1HSD17B10TSHR | |
| SCHEMBL14963903 | 0.71 | ALDH1A1 (0.73) | KDM4ESMN1; SMN2ALDH1A1HSD17B10TSHR | |
| SCHEMBL1707863 | 0.69 | SMN1; SMN2 (0.53) | KDM4ESMN1; SMN2ALDH1A1KMT2ALMNA | |
| SCHEMBL14963908 | 0.69 | LMNA (0.64) | KDM4ESMN1; SMN2ALDH1A1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| EP-2440541-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143733-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | GPR119, INSR, GLP1R | KDM4E 3896/4885SMN1; SMN2 4287/4885ALDH1A1 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.